Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs, and sutimlimab's potential to improve treatment earned it a breakthrough designation from the FDA.

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

ANSWER: Whether stents are beneficial in people with stable coronary artery disease remains somewhat controversial. Although ...

For those with CAD, medication may be necessary to control cholesterol, regulate blood pressure, or prevent blood clots. Taking medications as prescribed by a healthcare provider helps lower the ...

View all information regarding the medicines that are manufactured by Cad Pharma Inc including its generic drug name, trade name, how to use, the price, and its composition.

CathWorks has completed the enrolment for a randomised controlled trial (RCT), evaluating the FFRangio system in diagnosing ...